Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), 4D Molecular Therapeutics (FDMT) and Carisma Therapeutics (CARM)
Express News | Carisma Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q2 Financial Results
Express News | Carisma Anticipates Its Cash And Equivalents Sufficient To Sustain Its Planned Operations Into Q3 Of 2025
Carisma Therapeutics GAAP EPS of -$0.27 Beats by $0.03, Revenue of $9.2M Beats by $5.28M
Carisma Therapeutics | 10-Q: Quarterly report
Express News | Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Express News | Carisma Therapeutics Q2 Collaboration Revenue USD 9.197 Million
Press Release: Carisma Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Carisma Therapeutics 2Q Loss $11.2M >CARM
Express News | Carisma Therapeutics Announces Expansion of Its Scientific Advisory Board
Can Carisma Therapeutics (NASDAQ:CARM) Afford To Invest In Growth?
Parker Institute Welcomes New Co-Directors for PICI Centers at Stanford, UCSF & Penn
Express News | Carisma Therapeutics Inc - Has Suspended Enrollment of New Patients in Its Phase 1 Clinical Trial for Ct-0508
Express News | Carisma Therapeutics - Co Determined to Focus Ex Vivo Oncology Clinical Development Efforts on Its Follow-on Product Candidate Ct-0525
Express News | Carisma Therapeutics Inc - Termination of Co's Manufacturing and Supply Agreement, by and Between Co and Novartis Is Effective July 31, 2024
Express News | Carisma Therapeutics : On June 26, Notified Novartis Pharmaceuticals of Termination of Co's Manufacturing & Supply Agreement Between Co & Novartis
Carisma Therapeutics: Regina Hodits and Björn Odlander Have Informed the Bd of Their Intention to Step Dn as Members Due to Other Professional Commitments >CARM
Express News | Carisma Therapeutics Announces Changes to Its Board of Directors
Why Are Carisma Therapeutics Shares Surging Friday?
Carisma Jumps as Drug Discovery Under Moderna Deal Leads to $2M Payment
No Data